Management of immune checkpoint inhibitor‐related adverse events: A review of case reports
Identifieur interne : 000E63 ( Ncbi/Merge ); précédent : 000E62; suivant : 000E64Management of immune checkpoint inhibitor‐related adverse events: A review of case reports
Auteurs : Xiaoyan Si ; Peng Song ; Jun Ni ; Mingyi Di ; Chunxia He ; Li Zhang ; Xiaowei Liu ; Yue Li ; Hanping Wang ; Xiaoxiao Guo ; Jiaxin Zhou ; Lian Duan ; Xu Yang ; Mengzhao Wang ; Li ZhangSource :
- Thoracic Cancer [ 1759-7706 ] ; 2020.
Abstract
Immune checkpoint inhibitors represent a major breakthrough in cancer therapy. Immune‐related adverse events (irAEs) may occur during treatment due to their unique mechanism of action. Management of irAEs is based on clinical experience because it is not easy to conduct prospective trials to evaluate the best treatment strategy. Using a combination of search terms in the PubMed and Embase databases, we reviewed all cases in the English language citing toxicities associated with either pembrolizumab, nivolumab, ipilimumab, atezolizumab, tremelimumab, durvalumab, avelumab or any combination of these agents published before 20 May 2019. A total of 128 reports with 239 cases were included in the study. Here, we summarize the spectrum of toxicities, safety in special patients, rechallenging after irAEs and agents used for treatment of irAEs in those reports.
Url:
DOI: 10.1111/1759-7714.13315
PubMed: 31970923
PubMed Central: 7049490
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000B13
- to stream Pmc, to step Curation: 000B13
- to stream Pmc, to step Checkpoint: 000109
Links to Exploration step
PMC:7049490Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Management of immune checkpoint inhibitor‐related adverse events: A review of case reports</title><author><name sortKey="Si, Xiaoyan" sort="Si, Xiaoyan" uniqKey="Si X" first="Xiaoyan" last="Si">Xiaoyan Si</name><affiliation><nlm:aff id="tca13315-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Song, Peng" sort="Song, Peng" uniqKey="Song P" first="Peng" last="Song">Peng Song</name><affiliation><nlm:aff id="tca13315-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Ni, Jun" sort="Ni, Jun" uniqKey="Ni J" first="Jun" last="Ni">Jun Ni</name><affiliation><nlm:aff id="tca13315-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Di, Mingyi" sort="Di, Mingyi" uniqKey="Di M" first="Mingyi" last="Di">Mingyi Di</name><affiliation><nlm:aff id="tca13315-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="He, Chunxia" sort="He, Chunxia" uniqKey="He C" first="Chunxia" last="He">Chunxia He</name><affiliation><nlm:aff id="tca13315-aff-0002"></nlm:aff></affiliation></author><author><name sortKey="Zhang, Li" sort="Zhang, Li" uniqKey="Zhang L" first="Li" last="Zhang">Li Zhang</name><affiliation><nlm:aff id="tca13315-aff-0003"></nlm:aff></affiliation></author><author><name sortKey="Liu, Xiaowei" sort="Liu, Xiaowei" uniqKey="Liu X" first="Xiaowei" last="Liu">Xiaowei Liu</name><affiliation><nlm:aff id="tca13315-aff-0004"></nlm:aff></affiliation></author><author><name sortKey="Li, Yue" sort="Li, Yue" uniqKey="Li Y" first="Yue" last="Li">Yue Li</name><affiliation><nlm:aff id="tca13315-aff-0005"></nlm:aff></affiliation></author><author><name sortKey="Wang, Hanping" sort="Wang, Hanping" uniqKey="Wang H" first="Hanping" last="Wang">Hanping Wang</name><affiliation><nlm:aff id="tca13315-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Guo, Xiaoxiao" sort="Guo, Xiaoxiao" uniqKey="Guo X" first="Xiaoxiao" last="Guo">Xiaoxiao Guo</name><affiliation><nlm:aff id="tca13315-aff-0006"></nlm:aff></affiliation></author><author><name sortKey="Zhou, Jiaxin" sort="Zhou, Jiaxin" uniqKey="Zhou J" first="Jiaxin" last="Zhou">Jiaxin Zhou</name><affiliation><nlm:aff id="tca13315-aff-0007"></nlm:aff></affiliation></author><author><name sortKey="Duan, Lian" sort="Duan, Lian" uniqKey="Duan L" first="Lian" last="Duan">Lian Duan</name><affiliation><nlm:aff id="tca13315-aff-0008"></nlm:aff></affiliation></author><author><name sortKey="Yang, Xu" sort="Yang, Xu" uniqKey="Yang X" first="Xu" last="Yang">Xu Yang</name><affiliation><nlm:aff id="tca13315-aff-0009"></nlm:aff></affiliation></author><author><name sortKey="Wang, Mengzhao" sort="Wang, Mengzhao" uniqKey="Wang M" first="Mengzhao" last="Wang">Mengzhao Wang</name><affiliation><nlm:aff id="tca13315-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Zhang, Li" sort="Zhang, Li" uniqKey="Zhang L" first="Li" last="Zhang">Li Zhang</name><affiliation><nlm:aff id="tca13315-aff-0001"></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">31970923</idno><idno type="pmc">7049490</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049490</idno><idno type="RBID">PMC:7049490</idno><idno type="doi">10.1111/1759-7714.13315</idno><date when="2020">2020</date><idno type="wicri:Area/Pmc/Corpus">000B13</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000B13</idno><idno type="wicri:Area/Pmc/Curation">000B13</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000B13</idno><idno type="wicri:Area/Pmc/Checkpoint">000109</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000109</idno><idno type="wicri:Area/Ncbi/Merge">000E63</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Management of immune checkpoint inhibitor‐related adverse events: A review of case reports</title><author><name sortKey="Si, Xiaoyan" sort="Si, Xiaoyan" uniqKey="Si X" first="Xiaoyan" last="Si">Xiaoyan Si</name><affiliation><nlm:aff id="tca13315-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Song, Peng" sort="Song, Peng" uniqKey="Song P" first="Peng" last="Song">Peng Song</name><affiliation><nlm:aff id="tca13315-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Ni, Jun" sort="Ni, Jun" uniqKey="Ni J" first="Jun" last="Ni">Jun Ni</name><affiliation><nlm:aff id="tca13315-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Di, Mingyi" sort="Di, Mingyi" uniqKey="Di M" first="Mingyi" last="Di">Mingyi Di</name><affiliation><nlm:aff id="tca13315-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="He, Chunxia" sort="He, Chunxia" uniqKey="He C" first="Chunxia" last="He">Chunxia He</name><affiliation><nlm:aff id="tca13315-aff-0002"></nlm:aff></affiliation></author><author><name sortKey="Zhang, Li" sort="Zhang, Li" uniqKey="Zhang L" first="Li" last="Zhang">Li Zhang</name><affiliation><nlm:aff id="tca13315-aff-0003"></nlm:aff></affiliation></author><author><name sortKey="Liu, Xiaowei" sort="Liu, Xiaowei" uniqKey="Liu X" first="Xiaowei" last="Liu">Xiaowei Liu</name><affiliation><nlm:aff id="tca13315-aff-0004"></nlm:aff></affiliation></author><author><name sortKey="Li, Yue" sort="Li, Yue" uniqKey="Li Y" first="Yue" last="Li">Yue Li</name><affiliation><nlm:aff id="tca13315-aff-0005"></nlm:aff></affiliation></author><author><name sortKey="Wang, Hanping" sort="Wang, Hanping" uniqKey="Wang H" first="Hanping" last="Wang">Hanping Wang</name><affiliation><nlm:aff id="tca13315-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Guo, Xiaoxiao" sort="Guo, Xiaoxiao" uniqKey="Guo X" first="Xiaoxiao" last="Guo">Xiaoxiao Guo</name><affiliation><nlm:aff id="tca13315-aff-0006"></nlm:aff></affiliation></author><author><name sortKey="Zhou, Jiaxin" sort="Zhou, Jiaxin" uniqKey="Zhou J" first="Jiaxin" last="Zhou">Jiaxin Zhou</name><affiliation><nlm:aff id="tca13315-aff-0007"></nlm:aff></affiliation></author><author><name sortKey="Duan, Lian" sort="Duan, Lian" uniqKey="Duan L" first="Lian" last="Duan">Lian Duan</name><affiliation><nlm:aff id="tca13315-aff-0008"></nlm:aff></affiliation></author><author><name sortKey="Yang, Xu" sort="Yang, Xu" uniqKey="Yang X" first="Xu" last="Yang">Xu Yang</name><affiliation><nlm:aff id="tca13315-aff-0009"></nlm:aff></affiliation></author><author><name sortKey="Wang, Mengzhao" sort="Wang, Mengzhao" uniqKey="Wang M" first="Mengzhao" last="Wang">Mengzhao Wang</name><affiliation><nlm:aff id="tca13315-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Zhang, Li" sort="Zhang, Li" uniqKey="Zhang L" first="Li" last="Zhang">Li Zhang</name><affiliation><nlm:aff id="tca13315-aff-0001"></nlm:aff></affiliation></author></analytic><series><title level="j">Thoracic Cancer</title><idno type="ISSN">1759-7706</idno><idno type="eISSN">1759-7714</idno><imprint><date when="2020">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>Abstract</title><p>Immune checkpoint inhibitors represent a major breakthrough in cancer therapy. Immune‐related adverse events (irAEs) may occur during treatment due to their unique mechanism of action. Management of irAEs is based on clinical experience because it is not easy to conduct prospective trials to evaluate the best treatment strategy. Using a combination of search terms in the PubMed and Embase databases, we reviewed all cases in the English language citing toxicities associated with either pembrolizumab, nivolumab, ipilimumab, atezolizumab, tremelimumab, durvalumab, avelumab or any combination of these agents published before 20 May 2019. A total of 128 reports with 239 cases were included in the study. Here, we summarize the spectrum of toxicities, safety in special patients, rechallenging after irAEs and agents used for treatment of irAEs in those reports.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><pmc article-type="review-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Thorac Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Thorac Cancer</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1759-7714</journal-id><journal-id journal-id-type="publisher-id">TCA</journal-id><journal-title-group><journal-title>Thoracic Cancer</journal-title></journal-title-group><issn pub-type="ppub">1759-7706</issn><issn pub-type="epub">1759-7714</issn><publisher><publisher-name>John Wiley & Sons Australia, Ltd</publisher-name><publisher-loc>Melbourne</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31970923</article-id><article-id pub-id-type="pmc">7049490</article-id><article-id pub-id-type="doi">10.1111/1759-7714.13315</article-id><article-id pub-id-type="publisher-id">TCA13315</article-id><article-categories><subj-group subj-group-type="overline"><subject>Invited Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Invited Review</subject></subj-group></article-categories><title-group><article-title>Management of immune checkpoint inhibitor‐related adverse events: A review of case reports</article-title><alt-title alt-title-type="right-running-head">Immunotherapy‐related adverse events</alt-title><alt-title alt-title-type="left-running-head">X. Si <italic>et al</italic>.</alt-title></title-group><contrib-group><contrib id="tca13315-cr-0001" contrib-type="author"><name><surname>Si</surname><given-names>Xiaoyan</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2913-3045</contrib-id><xref ref-type="aff" rid="tca13315-aff-0001"><sup>1</sup></xref></contrib><contrib id="tca13315-cr-0002" contrib-type="author"><name><surname>Song</surname><given-names>Peng</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6316-5123</contrib-id><xref ref-type="aff" rid="tca13315-aff-0001"><sup>1</sup></xref></contrib><contrib id="tca13315-cr-0003" contrib-type="author"><name><surname>Ni</surname><given-names>Jun</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5939-8856</contrib-id><xref ref-type="aff" rid="tca13315-aff-0001"><sup>1</sup></xref></contrib><contrib id="tca13315-cr-0004" contrib-type="author"><name><surname>Di</surname><given-names>Mingyi</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7540-8383</contrib-id><xref ref-type="aff" rid="tca13315-aff-0001"><sup>1</sup></xref></contrib><contrib id="tca13315-cr-0005" contrib-type="author"><name><surname>He</surname><given-names>Chunxia</given-names></name><xref ref-type="aff" rid="tca13315-aff-0002"><sup>2</sup></xref></contrib><contrib id="tca13315-cr-0006" contrib-type="author"><name><surname>Zhang</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="tca13315-aff-0003"><sup>3</sup></xref></contrib><contrib id="tca13315-cr-0007" contrib-type="author"><name><surname>Liu</surname><given-names>Xiaowei</given-names></name><xref ref-type="aff" rid="tca13315-aff-0004"><sup>4</sup></xref></contrib><contrib id="tca13315-cr-0008" contrib-type="author"><name><surname>Li</surname><given-names>Yue</given-names></name><xref ref-type="aff" rid="tca13315-aff-0005"><sup>5</sup></xref></contrib><contrib id="tca13315-cr-0009" contrib-type="author"><name><surname>Wang</surname><given-names>Hanping</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3540-2280</contrib-id><xref ref-type="aff" rid="tca13315-aff-0001"><sup>1</sup></xref></contrib><contrib id="tca13315-cr-0010" contrib-type="author"><name><surname>Guo</surname><given-names>Xiaoxiao</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8583-5992</contrib-id><xref ref-type="aff" rid="tca13315-aff-0006"><sup>6</sup></xref></contrib><contrib id="tca13315-cr-0011" contrib-type="author"><name><surname>Zhou</surname><given-names>Jiaxin</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1664-3495</contrib-id><xref ref-type="aff" rid="tca13315-aff-0007"><sup>7</sup></xref></contrib><contrib id="tca13315-cr-0012" contrib-type="author"><name><surname>Duan</surname><given-names>Lian</given-names></name><xref ref-type="aff" rid="tca13315-aff-0008"><sup>8</sup></xref></contrib><contrib id="tca13315-cr-0013" contrib-type="author"><name><surname>Yang</surname><given-names>Xu</given-names></name><xref ref-type="aff" rid="tca13315-aff-0009"><sup>9</sup></xref></contrib><contrib id="tca13315-cr-0014" contrib-type="author"><name><surname>Wang</surname><given-names>Mengzhao</given-names></name><xref ref-type="aff" rid="tca13315-aff-0001"><sup>1</sup></xref></contrib><contrib id="tca13315-cr-0015" contrib-type="author" corresp="yes"><name><surname>Zhang</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="tca13315-aff-0001"><sup>1</sup></xref><address><email>zhanglipumch1026@sina.com</email></address></contrib></contrib-group><aff id="tca13315-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Department of Pulmonary and Critical Care Medicine</named-content><institution>Peking Union Medical College Hospital</institution><city>Beijing</city><country country="CN">China</country></aff><aff id="tca13315-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Department of Dermatology</named-content><institution>Peking Union Medical College Hospital</institution><city>Beijing</city><country country="CN">China</country></aff><aff id="tca13315-aff-0003"><label><sup>3</sup></label><named-content content-type="organisation-division">Department of Clinical Laboratory</named-content><institution>Peking Union Medical College Hospital</institution><city>Beijing</city><country country="CN">China</country></aff><aff id="tca13315-aff-0004"><label><sup>4</sup></label><named-content content-type="organisation-division">Department of Ophthalmology</named-content><institution>Peking Union Medical College Hospital</institution><city>Beijing</city><country country="CN">China</country></aff><aff id="tca13315-aff-0005"><label><sup>5</sup></label><named-content content-type="organisation-division">Department of Gastroenterology</named-content><institution>Peking Union Medical College Hospital</institution><city>Beijing</city><country country="CN">China</country></aff><aff id="tca13315-aff-0006"><label><sup>6</sup></label><named-content content-type="organisation-division">Department of Cardiology</named-content><institution>Peking Union Medical College Hospital</institution><city>Beijing</city><country country="CN">China</country></aff><aff id="tca13315-aff-0007"><label><sup>7</sup></label><named-content content-type="organisation-division">Department of Rheumatology</named-content><institution>Peking Union Medical College Hospital</institution><city>Beijing</city><country country="CN">China</country></aff><aff id="tca13315-aff-0008"><label><sup>8</sup></label><named-content content-type="organisation-division">Department of Endocrinology</named-content><institution>Peking Union Medical College Hospital</institution><city>Beijing</city><country country="CN">China</country></aff><aff id="tca13315-aff-0009"><label><sup>9</sup></label><named-content content-type="organisation-division">Department of Liver Surgery</named-content><institution>Peking Union Medical College Hospital</institution><city>Beijing</city><country country="CN">China</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break></break>Li Zhang, Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, No. 1 Shuaifuyuan Wangfujing, Dongcheng District, Beijing, 100730, China.<break></break>Tel: +86 10 6915 8760<break></break>Fax: +86 10 6915 5039<break></break>Email: <email>zhanglipumch1026@sina.com</email><break></break></corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2020</year></pub-date><volume>11</volume><issue>3</issue><issue-id pub-id-type="doi">10.1111/tca.v11.3</issue-id><fpage>498</fpage><lpage>504</lpage><history><date date-type="received"><day>24</day><month>11</month><year>2019</year></date><date date-type="rev-recd"><day>28</day><month>12</month><year>2019</year></date><date date-type="accepted"><day>29</day><month>12</month><year>2019</year></date></history><permissions><pmc-comment> © 2020 China Lung Oncology Group and Wiley Publishing Asia Pty Ltd </pmc-comment>
<copyright-statement content-type="article-copyright">© 2020 The Authors. <italic>Thoracic Cancer</italic> published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:TCA-11-498.pdf"></self-uri><abstract><title>Abstract</title><p>Immune checkpoint inhibitors represent a major breakthrough in cancer therapy. Immune‐related adverse events (irAEs) may occur during treatment due to their unique mechanism of action. Management of irAEs is based on clinical experience because it is not easy to conduct prospective trials to evaluate the best treatment strategy. Using a combination of search terms in the PubMed and Embase databases, we reviewed all cases in the English language citing toxicities associated with either pembrolizumab, nivolumab, ipilimumab, atezolizumab, tremelimumab, durvalumab, avelumab or any combination of these agents published before 20 May 2019. A total of 128 reports with 239 cases were included in the study. Here, we summarize the spectrum of toxicities, safety in special patients, rechallenging after irAEs and agents used for treatment of irAEs in those reports.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="tca13315-kwd-0001">Adverse event</kwd><kwd id="tca13315-kwd-0002">immune checkpoint inhibitor</kwd><kwd id="tca13315-kwd-0003">immunotherapy</kwd><kwd id="tca13315-kwd-0004">toxicity</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>CAMS Innovation Fund for Medical Sciences</funding-source><award-id>2016‐I2M‐1‐002</award-id></award-group></funding-group><counts><fig-count count="0"></fig-count><table-count count="2"></table-count><page-count count="7"></page-count><word-count count="4886"></word-count></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>March 2020</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.7.6.1 mode:remove_FC converted:01.03.2020</meta-value></custom-meta></custom-meta-group></article-meta></front></pmc><affiliations><list></list><tree><noCountry><name sortKey="Di, Mingyi" sort="Di, Mingyi" uniqKey="Di M" first="Mingyi" last="Di">Mingyi Di</name><name sortKey="Duan, Lian" sort="Duan, Lian" uniqKey="Duan L" first="Lian" last="Duan">Lian Duan</name><name sortKey="Guo, Xiaoxiao" sort="Guo, Xiaoxiao" uniqKey="Guo X" first="Xiaoxiao" last="Guo">Xiaoxiao Guo</name><name sortKey="He, Chunxia" sort="He, Chunxia" uniqKey="He C" first="Chunxia" last="He">Chunxia He</name><name sortKey="Li, Yue" sort="Li, Yue" uniqKey="Li Y" first="Yue" last="Li">Yue Li</name><name sortKey="Liu, Xiaowei" sort="Liu, Xiaowei" uniqKey="Liu X" first="Xiaowei" last="Liu">Xiaowei Liu</name><name sortKey="Ni, Jun" sort="Ni, Jun" uniqKey="Ni J" first="Jun" last="Ni">Jun Ni</name><name sortKey="Si, Xiaoyan" sort="Si, Xiaoyan" uniqKey="Si X" first="Xiaoyan" last="Si">Xiaoyan Si</name><name sortKey="Song, Peng" sort="Song, Peng" uniqKey="Song P" first="Peng" last="Song">Peng Song</name><name sortKey="Wang, Hanping" sort="Wang, Hanping" uniqKey="Wang H" first="Hanping" last="Wang">Hanping Wang</name><name sortKey="Wang, Mengzhao" sort="Wang, Mengzhao" uniqKey="Wang M" first="Mengzhao" last="Wang">Mengzhao Wang</name><name sortKey="Yang, Xu" sort="Yang, Xu" uniqKey="Yang X" first="Xu" last="Yang">Xu Yang</name><name sortKey="Zhang, Li" sort="Zhang, Li" uniqKey="Zhang L" first="Li" last="Zhang">Li Zhang</name><name sortKey="Zhang, Li" sort="Zhang, Li" uniqKey="Zhang L" first="Li" last="Zhang">Li Zhang</name><name sortKey="Zhou, Jiaxin" sort="Zhou, Jiaxin" uniqKey="Zhou J" first="Jiaxin" last="Zhou">Jiaxin Zhou</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E63 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000E63 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= PMC:7049490
|texte= Management of immune checkpoint inhibitor‐related adverse events: A review of case reports
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:31970923" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |